Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476020 | 1.00 | HSD11B1 (0.66) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL5472042 | 0.94 | HSD11B1 (0.62) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL5472049 | 0.94 | HSD11B1 (0.62) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL5473219 | 0.94 | HSD11B1 (0.62) | HSD11B1POLBMGLLKDM4EGAA | |
| SCHEMBL5470757 | 0.91 | MAPT (0.59) | HSD11B1POLBKDM4EALDH1A1 | |
| SCHEMBL5470754 | 0.91 | MAPT (0.59) | HSD11B1POLBKDM4EALDH1A1 | |
| SCHEMBL5477436 | 0.88 | MAPT (0.59) | HSD11B1POLBKDM4EALDH1A1 | |
| SCHEMBL5475174 | 0.88 | MAPT (0.59) | HSD11B1POLBKDM4EALDH1A1 | |
| SCHEMBL5478093 | 0.88 | MAPT (0.59) | HSD11B1POLBKDM4EALDH1A1 | |
| SCHEMBL5468368 | 0.86 | HSD11B1 (0.82) | HSD11B1POLBMGLLKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | claimed |
| EP-1685101-A1 | N-ACYLATED-3-(BENZOYL)-PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005047250-A1 | N-ACYLATED-3- (BENZOYL) - PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885POLB 1913/4885MGLL 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.